Saturday 14 November 2026 Daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
Market analysisEnterprise
The business of pharma
Subscribe free
Pipeline & R&D

Yarrow Bioscience says $268.9M cash funds Graves' disease antibody trial into 2030

The US biotech reported Q3 2026 results, with enrolment continuing in the DIRECTION-GD trial of YB-101 and Phase 2a topline data due in the second half of 2027.

12 Nov 2026 · Yarrow Bioscience, Inc. YARW · Company news

Yarrow Bioscience reported its third-quarter 2026 results on 12 November 2026. The company said enrolment is continuing in DIRECTION-GD, a Phase 2a/2b trial of its lead candidate YB-101 in Graves' disease, with or without thyroid eye disease.

YB-101 is an anti-TSHR antibody and holds Fast Track designation from the US Food and Drug Administration. Yarrow expects Phase 2a topline data in the second half of 2027.

The company ended September with $268.9 million in cash, following a public offering of roughly $172.5 million. Yarrow expects this cash to fund operations into 2030.

The information comes from the company's own announcement. Only the summary was available, so further financial and clinical details from the full release are not covered here.

Why it matters

  • Fast Track status, which is intended to speed development and review of drugs for serious conditions, applies to YB-101; teams tracking Graves' disease pipelines can note its progress.
  • The next clinical milestone to watch is Phase 2a topline data from DIRECTION-GD in the second half of 2027.
  • The cash runway into 2030 suggests the company can fund the trial through its planned readout, based on the company's own guidance.

Company's press release (SEC filing): Yarrow Bioscience, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →